• BioStrand secures second VLAIO research grant

    Thursday January 13th 2022

  • Biotalys and Olon enter into long-term partnership for the production of protein-based biocontrols

    Wednesday January 12th 2022

  • Biohaven enters exclusive license and research collaboration agreement with KU Leuven to advance first-in-class TRPM3 antagonists for the treatment of pain

    Wednesday January 12th 2022

  • Oxurion provides update on clinical pipeline progress

    Friday January 7th 2022

  • Ardena expands capacity to satisfy Novavax COVID vaccine demand

    Thursday January 6th 2022

  • Belgian research team uses AI to explain cell diversity in the fly brain

    Thursday January 6th 2022

  • Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

    Thursday January 6th 2022

  • Peter Scheyltjens (52), CEO en oprichter van de Advipro Groep, geeft de fakkel door aan zijn rechterhand Toon Witvrouwen (35)

    Thursday December 23rd 2021

  • Your news here?

  • VIB research at the basis of experimental gene therapy against dementia

    Wednesday December 22nd 2021

  • Biotalys and Biobest enter into strategic partnership to expand reach of novel biocontrol solutions

    Monday December 20th 2021

  • argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

    Monday December 20th 2021

Strategic Partners